Whereas other health economic analyses are used to evaluate the costs and outcomes of the interventions compared to arrive at their economic efficiency, budget-impact analysis (BIA) provides a down-stream estimate of total financial consequences within a specific healthcare budget from which to assess affordability. For example, a BIA can predict how a change in the casemix of patients or mix of therapies used to treat a particular condition will affect the trajectory of spending on that condition from a budgeting perspective. It is used for budget planning, forecasting and for predicting changes in premiums or reimbursements. The perspective is usually that of the specific healthcare decision-maker. A paper by Haddad et al. showed how dose-dependent drugs could be cost-beneficial at a high dose level, by reducing the net resource utilization for immune-deficient patients. In the area of acute anticoagulant reversal, using data provided by a large healthcare system, Dr. Jones and colleagues investigated the budget impact of treating patients with alternative anticoagulant-reversal protocols.
In a similar fashion, as one of our services, we can provide to investigators a budget-impact analysis product where the perspective can be the hospital budget, CMS’ budgets, the VA, or the NIH.